A Retrospective Study of Gemcitabine Plus Nab-Paclitaxel for Advanced Pancreatic Cancer Refractory to Gemcitabine Monotherapy

• DOI: 10.21873/anticanres.16919
• Publication Date: 2024-02-29T14:35:16Z
• Authors: MARIKO NISHIOKA; NAOHIRO OKANO; MASASHI WAKABAYASHI; TAKASHI IKENO; MASATO HAYASHI; TOMONORI MIZUTANI; FUMIO NAGASHIMA; JUNJI FURUSE
• Keywords: Refractory (planetary science); FOLFIRINOX

Background/Aim: This study aimed to investigate the efficacy and safety of gemcitabine (GEM) plus nab-paclitaxel (nab-PTX), termed GnP, which is limited, in patients with advanced pancreatic cancer (PC) who show good tolerance GEM monotherapy prior being refractory it. Patients Methods: We retrospectively analyzed data locally or metastatic PC received followed by GnP between December 2014 March 2019, regardless treatment line. Results: A total 14 after becoming were included this study. Eight nab-PTX-naïve group, seven whom treated as first-line chemotherapy, one was modified FOLFIRINOX treatment. The other six nab-PTX reintroduction group. In all maintenance therapy prevent adverse events, such peripheral neuropathy fatigue. Two group showed partial response none group; median progression-free survival 7.6 1.4 months overall 9.4 6.2 months, respectively. analysis, grade 3 anemia observed patient while remaining events 1 2. Conclusion: safe effective even GEM-refractory PC, can be an option for PC.